Utility of angiotensin receptor blockers in heart failure;Utilidad de los antagonistas de los receptores de angiotensina II en la insuficiencia cardíaca

Revista Clinica Espanola

Volumn 203, Issue 1, 2003, Pages 28-32

  Barrious Alonso, V ^a   Campuzano Ruiz, R ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN I; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN HEXETIL; CAPTOPRIL; CATHEPSIN G; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INOTROPIC AGENT; LOSARTAN; NEUROHORMONE; PLACEBO; RENIN; TISSUE PLASMINOGEN ACTIVATOR; VALSARTAN; VASODILATOR AGENT;

ADRENERGIC SYSTEM; ARTICLE; CLINICAL PRACTICE; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG USE; ENZYME INHIBITION; HEART FAILURE; HORMONAL REGULATION; HORMONE SYNTHESIS; HUMAN; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; PATIENT CARE; PREVALENCE; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME;

EID: 0037229276     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1157/13042186     Document Type: Article

References (26)

1. Swedberg K, Eneroth P, Kjekshus J, Withelmensen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990;82:1730-6.
2. Ruilope LM, Barrios V, Volpe M. Renal implications of the renin-angiotensin-aldosterone system blockade in heart failure. J Hypertens 2000;18: 1545-61.
3. Barrios V, Ortega J. ACE inhibitors in the treatment of heart failure. Heart Failure 1999; Train Lett 7:2-5.
4. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systemic overview of data from individual patients. Lancet 2000;35:1575-81.
5. Task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology: Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22: 1527-60.
6. Hunt SA, Baker DW, Chin MW, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: exective summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 guidelines for the evaluation and management of heart failure). Circulation 2001;104:2996-3007.
7. Benedict CR, Francis GS, Shelton B et al for the SOLVD investigators. Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. Am J Cardiol 1995;75:1151-7.
8. Juillerat L, Nussberger J, Menard J, Mooser V, Christen Y, Waeber B, Graft P, Brunner H. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 1990;16:564-72.
9. Roig E, Pérez-Villa F, Morales M, Jiménez W, Orús J, Heras M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000;21: 53-7.
10. Ferrari R, Guardigli G. Cicchitelli G, Valgimigli M, Soukhomovskaia O, Ceconi C. Cardioprotection with ACE inhibitors non-angiotensin II-related mechamisms. Eur Heart J Supplements 2000; 2 (Suppl I): I22-8.
11. Ruilope LM, Barrios V, Segura J, Campo C. The kidney in heart failure: role of angiotensin II. Curr Opin Nephrol Hypertens 1999;8: 153-6.
12. Lombera F, Barrios V, Soria F, Placer L, Cruz JM, Tomás L, et al. Guías de práctica clínica cle la Sociedad Española de Cardiología en hipertensión arterial. Rev Esp Cardiol 2000;53:66-90.
13. Remme WJ. Heart failure management: why evidence does not influence clinical practice. Eur Heart J Supplements 2000;2(Suppl I) I15-21.
14. Barrios V, Tamargo J, Llisterri JL, Palazuelos V, Lozano JV, Prieto L, et al. Encuesta sobre la situación de la insuficiencia cardíaca en Atención Primaria. Rev Esp Cardiol 2000; 53 (Suppl 2):60.
15. Meffert S, Stoll M, Steckelings UM, Bottari SP, Unger T. The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Mol Cell Endocrinol 1996;122:59-67.
16. Ruilope LM, Barrios V. Pharmacologic treatment in hypertensive heart disease. En: Crawford MH, DiMarco JP, editores. Cardiology. London: Mosby: 2001. p. 8.1-8.
17. Gottlieb S, Dickstein K, Fleck E, Kustis J, Levine TB, LeJemtel T, et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993;88: 1602-9.
18. Dickstein K, Chang P, Willenheimer R, Haunso S, Remes J, Hall C, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise perfomance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 1995;26:438-45.
19. Riegger GAJ, Bouzo H, Petr P, Münz J, Spacek R, Pethig H, et al. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Circulation 1999;100:2224-30.
20. Pitt B, Segal R, Martínez FA, Meurers G, Cowley AJ, Thomas I, et al, on behalf of ELITE Study Investigators. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.
21. Pitt B, Poole-Wilson PA, Segal R, Martínez FA, Dickstein K, Camm AJ, et al, on behalf of ELITE Study Investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.
22. Azizi M, Linhart A, Alexander J, Goldberg A, Menten J, Sweet J, Menard J. Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients. J Hypertens 2000;342:1139-47.
23. Cohn JN, Tognoni G for the Valsartan Heart Failure Trial investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
24. Swedberg K, Pfeffer M, Granger C, Held P, McMurray J, Ohlin G, et al, for the CHARM-programme investigators. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and Design. J Card Fail 1999;5:276-82.
25. Barrios V, Ruilope LM. Hypertension with left ventricular hypertrophy/diastolic dysfunction. En: Sleight P, Bakris G, Mancia G, Opie FML, editores. Clinical cases in hypertension. Specific treatment strategies (volume two). Richmond upon Thames (Reino Unido): PAN Communications; 2000. p. 16-22.
26. Dickstein K, Kjekshus J and the OPTIMAAL steering committee for the optimal study group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360:752-60.